Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
40.2M
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
6.31M
-
Shares change
-
-777K
-
Total reported value, excl. options
-
$43.7M
-
Value change
-
-$8.44M
-
Number of buys
-
17
-
Number of sells
-
-17
-
Price
-
$6.92
Significant Holders of Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) as of Q3 2021
46 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2021.
Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.31M shares
of 40.2M outstanding shares and own 15.69% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.56M shares), Ikarian Capital, LLC (480K shares), ORBIMED ADVISORS LLC (450K shares), VANGUARD GROUP INC (436K shares), PERCEPTIVE ADVISORS LLC (422K shares), CITADEL ADVISORS LLC (346K shares), BOXER CAPITAL, LLC (209K shares), BAKER BROS. ADVISORS LP (200K shares), TWO SIGMA ADVISERS, LP (169K shares), and GOLDMAN SACHS GROUP INC (156K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.